Audit by comptroller and auditor general of india in biotech sector

Introduction

The Comptroller and Auditor General (CAG) of India is a constitutional authority responsible for auditing the receipts and expenditure of the Union and State Governments, government departments, public sector undertakings and other entities as provided under law. In the biotechnology sector, CAG audits play an important role in ensuring financial accountability, transparency, regulatory compliance and effective utilisation of public funds.

The biotechnology sector involves substantial government investment in scientific research, genetic engineering, pharmaceutical development, vaccine production, agricultural biotechnology, stem cell research and bioinformatics. Government institutions such as the Department of Biotechnology (DBT), Biotechnology Industry Research Assistance Council (BIRAC), Indian Council of Medical Research (ICMR) and publicly funded research laboratories undertake activities involving significant financial resources.

CAG audits examine whether these resources are used economically, efficiently and effectively. They also assess whether biotechnology programmes comply with applicable financial rules, procurement procedures, research funding conditions and statutory requirements.

Constitutional and legal framework governing CAG audits

1. Article 148 of the Indian Constitution

Article 148 establishes the office of the Comptroller and Auditor General of India.

The CAG is appointed by the President of India and enjoys constitutional protection concerning independence and conditions of service.

In the biotechnology sector, this constitutional independence is important because government-funded research institutions and public biotechnology organisations must remain accountable for the utilisation of public money.

2. Article 149 of the Indian Constitution

Article 149 provides that the CAG shall perform such duties and exercise such powers in relation to the accounts of the Union, States and other authorities or bodies as prescribed by Parliament.

The Comptroller and Auditor General's Duties, Powers and Conditions of Service Act, 1971, provides the principal statutory framework for exercising these responsibilities.

This enables the CAG to examine expenditure and financial management in government-supported biotechnology programmes.

3. Article 150 of the Indian Constitution

Article 150 provides that the accounts of the Union and States shall be kept in such form as the President may prescribe on the advice of the CAG.

This provision supports standardised accounting practices and financial reporting.

Biotechnology institutions receiving public funds must maintain appropriate financial records to demonstrate how research grants, laboratory investments and development expenditure are utilised.

4. Article 151 of the Indian Constitution

Article 151 deals with the submission of CAG audit reports.

Reports relating to Union Government accounts are submitted to the President, who causes them to be laid before each House of Parliament.

Reports concerning State Government accounts are submitted to the Governor, who causes them to be laid before the State Legislature.

This mechanism ensures legislative scrutiny of public expenditure in biotechnology and other scientific sectors.

Comptroller and Auditor General's Duties, Powers and Conditions of Service Act, 1971

The CAG's constitutional responsibilities are further regulated by the Comptroller and Auditor General's Duties, Powers and Conditions of Service Act, 1971.

Important provisions include:

Section 13 – Audit of expenditure from the Consolidated Fund

This section empowers the CAG to audit expenditure from the Consolidated Fund of India and the Consolidated Funds of States and Union Territories having Legislative Assemblies.

In biotechnology, this may include government expenditure on research laboratories, vaccine development programmes, scientific equipment and biotechnology infrastructure.

Section 14 – Audit of receipts and expenditure of bodies and authorities substantially financed by grants or loans

This provision allows the CAG to audit the receipts and expenditure of qualifying bodies and authorities substantially financed by government grants or loans.

It is relevant to biotechnology research institutions and organisations receiving substantial government financial assistance.

Section 15 – Audit of grants or loans given for specific purposes

This section concerns the audit of grants and loans given for specific purposes.

For example, if a government department provides financial assistance to a biotechnology institution for vaccine research or development of agricultural biotechnology, the CAG may examine whether the funds were utilised for the intended purpose.

Section 16 – Audit of receipts

This section empowers the CAG to audit government receipts and examine whether appropriate procedures have been established to ensure effective assessment, collection and allocation of revenue.

It may be relevant to government biotechnology institutions generating revenue through licensing, research services or other activities.

Section 18 – Powers of the CAG in connection with audit

The CAG has powers to inspect offices, call for accounts, books and other relevant documents and obtain information necessary for conducting audits.

These powers support the examination of financial records maintained by biotechnology departments and publicly funded research organisations.

Scope of CAG audits in the biotechnology sector

CAG audits in biotechnology may cover several important areas.

1. Audit of research grants and government funding

Government-funded biotechnology research requires substantial financial resources.

The CAG examines whether research grants are allocated according to approved objectives and whether institutions comply with the conditions attached to financial assistance.

Important audit considerations include:

Proper utilisation of research grants.

Compliance with approved project budgets.

Verification of expenditure records.

Prevention of diversion of funds.

Timely submission of utilisation certificates.

Recovery or adjustment of unspent balances where required.

2. Audit of vaccine development and pharmaceutical programmes

Government-funded vaccine research and biotechnology-based pharmaceutical development involve significant expenditure.

The CAG may examine procurement, research funding, infrastructure development and implementation of public health programmes.

The audit may also assess whether financial resources were used efficiently and whether projects achieved their approved objectives.

3. Audit of biotechnology research infrastructure

Biotechnology laboratories require specialised equipment, controlled environments and expensive scientific instruments.

The CAG may examine whether:

Laboratory equipment was procured through transparent procedures.

Equipment was installed and made operational.

Maintenance contracts were properly administered.

Publicly funded facilities were adequately utilised.

Procurement expenditure provided value for money.

4. Audit of genetically modified crop research

Government-funded agricultural biotechnology programmes may involve research into genetically modified crops, agricultural productivity and environmental applications.

The CAG may examine the financial administration of these programmes and whether public funds were utilised according to approved research objectives.

The audit of expenditure must be distinguished from the scientific and statutory biosafety approval functions performed by competent regulatory authorities.

5. Audit of biotechnology public sector organisations

The CAG may audit qualifying government companies and public sector undertakings under the Companies Act, 2013, and the CAG Act, 1971.

Such audits may examine financial statements, internal controls, procurement procedures, project expenditure and operational performance.

Types of audits applicable to biotechnology institutions

1. Financial audit

A financial audit examines whether financial statements and expenditure records present a reliable account of the institution's financial position.

In biotechnology institutions, this may involve checking research grants, laboratory expenditure, salaries, equipment purchases and project-related payments.

2. Compliance audit

A compliance audit examines whether institutions follow applicable laws, regulations, financial rules, contractual obligations and government instructions.

For example, a biotechnology research organisation must comply with applicable procurement rules and grant conditions when purchasing laboratory equipment.

3. Performance audit

A performance audit evaluates whether government programmes achieve their intended objectives economically, efficiently and effectively.

In the biotechnology sector, performance audits may assess:

Progress of publicly funded research programmes.

Effectiveness of vaccine development initiatives.

Utilisation of biotechnology infrastructure.

Achievement of research milestones.

Efficiency of government-funded innovation programmes.

4. Information technology audit

Biotechnology institutions increasingly use digital research platforms, genomic databases and laboratory information management systems.

IT audits may examine access controls, data integrity, cybersecurity, digital procurement systems and the reliability of financial information systems.

Role of CAG in ensuring biotechnology regulatory accountability

The CAG contributes to biotechnology governance by examining the financial and administrative effectiveness of government institutions.

However, it is important to distinguish financial and performance auditing from scientific regulatory approval.

For example, the Genetic Engineering Appraisal Committee (GEAC) performs statutory functions concerning specified activities involving genetically engineered organisms under the applicable environmental regulations.

Similarly, CDSCO regulates drugs and medical devices within its statutory jurisdiction.

The CAG does not replace these regulatory authorities. Instead, it can examine the financial administration, institutional performance and expenditure associated with their government-funded activities.

Its audit findings may identify weaknesses in procurement, project implementation, internal controls and utilisation of public resources.

Important case laws and judicial decisions

1. Arvind Gupta v. Union of India (2013)

Supreme Court of India, principles concerning public accountability and government expenditure

The Supreme Court has repeatedly emphasised that public resources must be administered in accordance with constitutional principles and public interest.

However, this case should not be treated as a direct authority on CAG auditing of biotechnology institutions. The broader legal principle is that government expenditure must remain subject to accountability and appropriate legal controls.

Legal significance: Publicly funded biotechnology projects must demonstrate proper financial administration, transparency and compliance with applicable government rules.

2. Centre for Public Interest Litigation v. Union of India (2012)

Supreme Court of India, (2012) 3 SCC 1 (2G Spectrum Case)

The Supreme Court examined the allocation of valuable natural resources and the principles governing government decision-making.

The Court emphasised transparency, fairness and public interest in the distribution of public resources.

Legal significance: Although the case concerned spectrum allocation rather than biotechnology, its principles are relevant to government-funded biotechnology programmes. Public research grants, scientific infrastructure and government resources should be administered through transparent and accountable procedures.

3. Natural Resources Allocation, In re, Special Reference No. 1 of 2012

Supreme Court of India, (2012) 10 SCC 1

The Supreme Court considered questions concerning the allocation of natural resources and clarified that the Constitution does not mandate a single method of allocation in every situation.

The Court recognised that government decisions must comply with constitutional principles, including fairness, transparency and public interest.

Legal significance: This decision is relevant to the allocation of public funds for biotechnology research, scientific infrastructure and innovation programmes. Government authorities must adopt legally appropriate and transparent funding procedures.

4. Subramanian Swamy v. Arun Shourie (2014)

Supreme Court of India, principles concerning public accountability and institutional responsibility

The Supreme Court has recognised the importance of accountability in the exercise of public functions and the proper administration of government institutions.

This decision is not a direct precedent concerning CAG audits in the biotechnology sector. It may be discussed only in the broader context of public accountability.

Legal significance: Biotechnology institutions receiving public money must maintain appropriate institutional controls, financial records and mechanisms for accountability.

5. Association for Democratic Reforms v. Union of India (2002)

Supreme Court of India, (2002) 5 SCC 294

The Supreme Court recognised the importance of transparency in democratic governance and the public's right to information concerning candidates contesting elections.

The judgment strengthened the broader constitutional principle that transparency is essential for meaningful public accountability.

Legal significance: Although unrelated directly to biotechnology audits, the transparency principle supports public scrutiny of government-funded scientific programmes and responsible disclosure of relevant audit findings.

Parliamentary oversight and Public Accounts Committee

The CAG's audit reports become important instruments of legislative accountability.

The Public Accounts Committee (PAC) examines CAG reports and evaluates whether public expenditure has been incurred in accordance with parliamentary authorisation.

In biotechnology, the PAC may examine issues such as:

Unproductive expenditure on research infrastructure.

Delays in government-funded scientific projects.

Improper utilisation of research grants.

Financial irregularities in biotechnology institutions.

Weak internal financial controls.

Failure to achieve approved programme objectives.

The PAC may seek explanations from government departments and recommend corrective measures.

This mechanism strengthens democratic oversight of public expenditure in the biotechnology sector.

Challenges in auditing the biotechnology sector

CAG audits in biotechnology face several practical and institutional challenges.

1. Technical complexity: Biotechnology projects involve specialised scientific processes, making it difficult to assess project performance without appropriate technical expertise.

2. Long research timelines: Biotechnology research may require several years before producing commercially or scientifically measurable results.

3. Uncertain research outcomes: Scientific research involves uncertainty, and unsuccessful experiments do not automatically indicate financial irregularity.

4. Procurement difficulties: Advanced laboratory equipment, specialised reagents and imported scientific instruments create complex procurement requirements.

5. Intellectual property concerns: Patent applications, confidential research information and licensing agreements may require careful examination while protecting legitimate confidentiality.

6. Fragmented institutional responsibility: Biotechnology programmes frequently involve several ministries, research institutions, universities and private-sector partners.

Conclusion

The audit by the Comptroller and Auditor General of India in the biotechnology sector is an important mechanism for ensuring transparency, financial discipline and accountability in publicly funded scientific research.

Articles 148–151 of the Indian Constitution and the Comptroller and Auditor General's Duties, Powers and Conditions of Service Act, 1971, establish the constitutional and statutory foundation of CAG auditing.

The audit process covers research grants, vaccine development, laboratory infrastructure, biotechnology public sector organisations, agricultural biotechnology programmes and government-funded innovation initiatives.

Judicial decisions such as Centre for Public Interest Litigation v. Union of India, Natural Resources Allocation, In re and Association for Democratic Reforms v. Union of India provide broader principles concerning transparency, public interest and accountable administration.

Ultimately, effective CAG auditing helps prevent financial irregularities, improve the utilisation of public research funds and strengthen institutional governance. It ensures that biotechnology development remains consistent with financial accountability, public welfare and responsible scientific advancement.